118 related articles for article (PubMed ID: 22698669)
1. Understanding the drug resistance mechanism of hepatitis C virus NS3/4A to ITMN-191 due to R155K, A156V, D168A/E mutations: a computational study.
Pan D; Xue W; Zhang W; Liu H; Yao X
Biochim Biophys Acta; 2012 Oct; 1820(10):1526-34. PubMed ID: 22698669
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435.
Xue W; Pan D; Yang Y; Liu H; Yao X
Antiviral Res; 2012 Jan; 93(1):126-37. PubMed ID: 22127068
[TBL] [Abstract][Full Text] [Related]
3. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
Xue W; Wang M; Jin X; Liu H; Yao X
Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
[TBL] [Abstract][Full Text] [Related]
4. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
[TBL] [Abstract][Full Text] [Related]
5. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
Xue W; Ban Y; Liu H; Yao X
J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
[TBL] [Abstract][Full Text] [Related]
6. Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V).
Ezat AA; El-Bialy NS; Mostafa HI; Ibrahim MA
Protein J; 2014 Feb; 33(1):32-47. PubMed ID: 24374429
[TBL] [Abstract][Full Text] [Related]
7. Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease.
Wang H; Geng L; Chen BZ; Ji M
Biochem Cell Biol; 2014 Oct; 92(5):357-69. PubMed ID: 25178998
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.
Guo Z; Black S; Hu Y; McMonagle P; Ingravallo P; Chase R; Curry S; Asante-Appiah E
J Biol Chem; 2017 Apr; 292(15):6202-6212. PubMed ID: 28228479
[TBL] [Abstract][Full Text] [Related]
9. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution.
Lim SR; Qin X; Susser S; Nicholas JB; Lange C; Herrmann E; Hong J; Arfsten A; Hooi L; Bradford W; Nájera I; Smith P; Zeuzem S; Kossen K; Sarrazin C; Seiwert SD
Antimicrob Agents Chemother; 2012 Jan; 56(1):271-9. PubMed ID: 22064535
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Forestier N; Larrey D; Guyader D; Marcellin P; Rouzier R; Patat A; Smith P; Bradford W; Porter S; Blatt L; Seiwert SD; Zeuzem S
J Hepatol; 2011 Jun; 54(6):1130-6. PubMed ID: 21145848
[TBL] [Abstract][Full Text] [Related]
11. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
[TBL] [Abstract][Full Text] [Related]
12. Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease.
Nagpal N; Goyal S; Wahi D; Jain R; Jamal S; Singh A; Rana P; Grover A
Gene; 2015 Oct; 570(1):115-21. PubMed ID: 26055089
[TBL] [Abstract][Full Text] [Related]
13. Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations.
Guan Y; Sun H; Pan P; Li Y; Li D; Hou T
Mol Biosyst; 2015 Sep; 11(9):2568-78. PubMed ID: 26219385
[TBL] [Abstract][Full Text] [Related]
14. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior.
Rajagopalan R; Misialek S; Stevens SK; Myszka DG; Brandhuber BJ; Ballard JA; Andrews SW; Seiwert SD; Kossen K
Biochemistry; 2009 Mar; 48(11):2559-68. PubMed ID: 19209850
[TBL] [Abstract][Full Text] [Related]
15. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
He Y; King MS; Kempf DJ; Lu L; Lim HB; Krishnan P; Kati W; Middleton T; Molla A
Antimicrob Agents Chemother; 2008 Mar; 52(3):1101-10. PubMed ID: 18086851
[TBL] [Abstract][Full Text] [Related]
16. Effect of D168V mutation in NS3/4A HCV protease on susceptibilities of faldaprevir and danoprevir.
Meeprasert A; Hannongbua S; Kungwan N; Rungrotmongkol T
Mol Biosyst; 2016 Nov; 12(12):3666-3673. PubMed ID: 27731877
[TBL] [Abstract][Full Text] [Related]
17. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
[TBL] [Abstract][Full Text] [Related]
18. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
19. Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach.
Palanisamy N; Lennerstrand J
Interdiscip Sci; 2018 Mar; 10(1):143-156. PubMed ID: 27311576
[TBL] [Abstract][Full Text] [Related]
20. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.
Lin C; Gates CA; Rao BG; Brennan DL; Fulghum JR; Luong YP; Frantz JD; Lin K; Ma S; Wei YY; Perni RB; Kwong AD
J Biol Chem; 2005 Nov; 280(44):36784-91. PubMed ID: 16087668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
